MicroRNA-targeting therapeutics for hepatitis C

MiR-122 is a liver-specific microRNA (miRNA) that plays a pivotal role in regulating hepatic functions such as lipid metabolism and stress response. The observation that hepatitis C virus (HCV) could only replicate in miR-122-positive hepatocytes led to the discovery that miR-122 is essential for HC...

Full description

Saved in:
Bibliographic Details
Published in:Archives of pharmacal research 2014, 37(3), , pp.299-305
Main Authors: Baek, Jihae, Kang, Soowon, Min, Hyeyoung
Format: Article
Language:English
Subjects:
Animals
Clinical Trials as Topic - methods
Drug Delivery Systems - trends
Drugs, Investigational - administration & dosage
Hepatitis C - drug therapy
Hepatitis C - genetics
Humans
Medicine
MicroRNAs - antagonists & inhibitors
MicroRNAs - physiology
Oligonucleotides
Pharmacology/Toxicology
Pharmacy
Phosphorothioate Oligonucleotides - administration & dosage
Report on Investigational Drugs
약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MiR-122 is a liver-specific microRNA (miRNA) that plays a pivotal role in regulating hepatic functions such as lipid metabolism and stress response. The observation that hepatitis C virus (HCV) could only replicate in miR-122-positive hepatocytes led to the discovery that miR-122 is essential for HCV replication, and miR-122 is now one of the crucial host factors for anti-HCV therapy. Currently, the most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic acid-modified oligonucleotide antagonizing miR-122. This review serves to provide information on the discovery and development of SPC3649, the first miRNA-targeted drug to enter human clinical trials, and introduce other miR-122-targeting therapeutics being developed for hepatitis C.
ISSN:0253-6269
1976-3786
DOI:10.1007/s12272-013-0318-9